PWM
DSGN icon

Palumbo Wealth Management’s Design Therapeutics DSGN Stock Holding History

Palumbo Wealth Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
71,744
+336
+0.5% +$4.19K 0.22% 76
2026
Q1 		$760K Buy
71,408
+2,031
+3% +$20.6K 0.19% 86
2025
Q4 		$651K Buy
69,377
+17,296
+33% +$135K 0.16% 101
2025
Q3 		$392K Sell
52,081
-8,474
-14% -$42.4K 0.13% 112
2025
Q2 		$204K Buy
60,555
+2,277
+4% +$8.52K 0.06% 184
2025
Q1 		$225K Buy
58,278
+3,582
+7% +$17.1K 0.08% 159
2024
Q4 		$337K Buy
54,696
+17,922
+49% +$104K 0.13% 113
2024
Q3 		$198K Buy
36,774
+3,720
+11% +$17.5K 0.08% 141
2024
Q2 		$111K Buy
33,054
+16,082
+95% +$62.7K 0.05% 138
2024
Q1 		$68.4K Buy
+16,972
New +$45.3K 0.03% 134

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Palumbo Wealth Management's DSGN Position: Q2 2026 in Review

Palumbo Wealth Management increased its Design Therapeutics (DSGN) stake by 0.47% in Q2 2026, buying an estimated $4.19K and bringing the position to 71,744 shares worth $1.04M. The position accounts for 0.22% of the portfolio, ranked #76.

Palumbo Wealth Management first reported a position in DSGN in Q1 2024 and has held it in 10 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Palumbo Wealth Management held 71,744 shares of Design Therapeutics worth $1.04M as of Q2 2026.
  • Palumbo Wealth Management bought 336 Design Therapeutics shares in Q2 2026, an estimated $4.19K.
  • Design Therapeutics made up 0.22% of Palumbo Wealth Management's portfolio in Q2 2026, its #76 holding.
  • Palumbo Wealth Management first reported a position in Design Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Palumbo Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.